Edgewise Q2 2026 Results: Higher R&D Spending Widens the Net Loss

Edgewise Therapeutics (Nasdaq: EWTX) reported a Q2 2026 net loss of $57.3 million, or $0.53 per basic and diluted share, compared with $36.1 million, or $0.34 per share, a year earlier. Higher clinical development and personnel costs widened the loss, while the July 10 completion of the Servier transaction materially increased post-quarter liquidity and shifted the company’s focus entirely to cardiovascular programs.

Core Financial Results

Edgewise reported no revenue, consistent with its status as a clinical-stage biotechnology company. Operating expenses rose about 45% year over year, led by increased R&D activity for EDG-7500 and EDG-15400, patient rollover activity in the MESA open-label extension study, and higher personnel costs.

G&A expense also increased because of personnel-related costs, including stock-based compensation, as well as higher professional fees and other administrative expenses. Lower interest income provided less of an offset to operating losses than it did a year earlier.

Business and Pipeline Progress

The largest strategic development occurred after the quarter. Edgewise completed the sale of sevasemten and its muscular dystrophy business to Servier on July 10, receiving $1.55 billion in upfront cash and retaining eligibility for up to $1.1 billion in additional milestone payments. Total potential consideration is therefore as much as $2.65 billion, although the milestone portion is contingent.

The transaction leaves Edgewise focused on a cardiovascular pipeline consisting of EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for heart failure with preserved ejection fraction, and EDG-003 for an undisclosed target.

EDG-7500

Edgewise announced positive top-line results from the 12-week, open-label Phase 2 Part D CIRRUS-HCM trial in adults with obstructive and nonobstructive hypertrophic cardiomyopathy. The trial was designed to inform Phase 3 development, and the company expects to begin a Phase 3 trial in the fourth quarter of 2026.

The source did not provide detailed efficacy or safety figures from CIRRUS-HCM, so the importance of the result at this stage is the planned progression into late-stage testing rather than a quantified clinical comparison.

EDG-15400

EDG-15400 completed dosing in a randomized, double-blind, placebo-controlled Phase 1 study evaluating single and multiple ascending doses in healthy adults. Edgewise expects to initiate a Phase 2 trial in participants with heart failure with preserved ejection fraction during the second half of 2026.

Profitability and Balance Sheet

Cash, cash equivalents and marketable securities declined by $69.4 million during the first half of 2026, alongside increased clinical development spending. Liabilities changed only modestly, while stockholders’ equity decreased by $74.2 million from year-end.

The June 30 cash balance excluded the Servier payment because the transaction closed after quarter-end. Adding the $1.55 billion upfront payment produces a pro forma cash and securities balance of $2.01 billion before taxes and transaction-related costs. That figure also excludes the potential $1.1 billion of future milestone payments.

This post-transaction liquidity provides a larger funding base as Edgewise prepares to advance EDG-7500 into Phase 3 and EDG-15400 into Phase 2. However, the quarter’s higher R&D and G&A expenses show that development costs were already increasing before those planned trial starts.

Recent Insider Transactions

The supplied six-month insider summary shows purchases of 300,658 shares across six transactions and sales of 321,588 shares across five transactions. That represents net sales of 20,930 shares and a reported net-share change of negative 4.10%, with total insider holdings listed at approximately 487,400 shares.

The following are the latest 10 transactions in the supplied two-year record. The figures below are reported transaction values rather than share quantities.

These records establish the transaction types and reported amounts but do not, by themselves, indicate how insiders assess the company’s future prospects.

Risks Investors Need to Watch

• Clinical and regulatory execution: Positive Phase 2 top-line results do not ensure that EDG-7500 will reproduce those findings in Phase 3 or meet regulatory requirements.
• Greater portfolio concentration: Following the muscular dystrophy business sale, Edgewise is substantially dependent on EDG-7500 and the progress of its remaining cardiovascular pipeline.
• Continued expense growth: R&D and G&A expenses increased materially before the planned Phase 3 and Phase 2 trial starts, which may keep operating losses elevated as development advances.
• Contingent transaction value: Up to $1.1 billion of the Servier consideration depends on future milestones and should not be treated as current cash. Taxes and transaction costs will also reduce the stated pro forma balance.
• Early-stage pipeline uncertainty: EDG-15400 has completed Phase 1 dosing but has not yet produced Phase 2 results in patients with HFpEF.

Summary

Edgewise’s Q2 2026 results reflected rising investment in its clinical pipeline, with higher R&D and administrative costs widening the net loss. The Servier transaction substantially increased the company’s post-quarter financial resources while concentrating its strategy on cardiovascular disease. The next major points to monitor are the planned Phase 3 start for EDG-7500, the Phase 2 start for EDG-15400, and how quickly development spending grows against the expanded cash base.